NCT06392477招募中1 期
A Multicenter, Multiple Expansion Cohort Phase 1 Study Evaluating the Safety and Activity of SAR448501/DR-0201 as Multiple Ascending Doses in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- Sanofi
- 入组人数
- 96
- 试验地点
- 16
- 主要终点
- Incidence of treatment-emergent adverse event (TEAE)
研究概览
简要总结
This is an open-label, multiple ascending dose (MAD), phase 1 study in adult patients with relapsed or refractory (R/R) B cell non-Hodgkin lymphoma (B-NHL). The purpose of the study is to identify possible optimal biological dosage(s) by assessing safety, tolerability, pharmacokinetics (PK), pharmacodynamics, clinical activity and immunogenicity of SAR448501/DR-0201.
The study duration per participant will be approximately 3 years, including a screening period of up to 28 days, a treatment period of 52 weeks, a safety follow-up period of approximately 28 days and a long-term follow-up period of every 3 months until withdrawal of consent, participant death or study closure, whichever is sooner.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants with R/R B-NHL which has failed at least 2 prior lines available life-prolonging standard therapy and without treatment options that are recognized to offer clinical benefit.
- •Adequate marrow reserve, renal function, and hepatic function.
- •Measurable disease defined as ≥ 1 bi-dimensionally measurable nodal lesion of > 1.5 cm in the longest dimension for participants with fluorodeoxyglucose (FDG)-avid disease for subtypes with nodular disease or at least one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest dimension.
- •Eastern Cooperative Oncology Group (ECOG) performance status 0-
- •Life expectancy of ≥ 12 weeks.
- •Use of a highly effective contraceptive measure for all males and all females of childbearing potential during study through 180 days post last dose; Females of childbearing potential need to have a negative serum pregnancy test within 7 days prior to first dose.
- •Tumor tissue block or 3 to 5 unstained slides from lymph node or other relevant biopsy collected in the past 12 months. Participants must be willing to provide a baseline and at least 1 on-treatment biopsy, unless not safely accessible.
- •Participants who have received prior CAR-T therapy must be >60 days post CAR-T at day of first dosing.
排除标准
- •Burkitt's or Burkitt's like lymphoma or lymphoplastic lymphoma.
- •Current history of central nervous system (CNS) involvement by malignancy.
- •Prior allogeneic stem cell transplantation except for those with follicular lymphoma (FL) and mantle cell lymphoma (MCL), who are excluded if transplant occurred less than 100 days prior to dosing or if they exhibit grade > 1 graft versus host disease.
- •Prior solid organ transplantation.
- •Autologous stem cell transplantation ≤ 100 days prior to dosing.
- •History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematous, rheumatoid arthritis, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjorgen's syndrome, Guillain-Barre-syndrome, multiple sclerosis vasculitis, or glomerulonephritis (participants with a remote history of, or well-controlled autoimmune disease, may be eligible).
- •Major surgery in the last 28 days prior to dosing.
- •Evidence of significant, uncontrolled concomitant disease that could affect compliance with study.
- •Current or past history of CNS disease (participants with remote history of non-lymphoma CNS disease and with no residual neurologic deficits may be eligible to enroll).
- •QT interval corrected by Fridericia's formula (QTcF) > 480 msec.
- •Significant cardiovascular disease.
- •Received any anticancer systemic therapy within 4 weeks prior to first drug administration or 5 half-lives of the drug, whatever is shorter. Treatment with corticosteroid ≤ 25 mg/day prednisone or equivalent is allowed. Inhaled and topical steroids are allowed.
- •Known infection with HIV, hepatitis B virus (HBV) or hepatitis C virus (HCV).
- •Active infection at baseline requiring systemic treatment with antimicrobial, antifungal, or antiviral agents in the 2 weeks prior to dosing.
- •Administration of a live, attenuated vaccine within 4 weeks prior to first drug administration or anticipation that such vaccine administration would be necessary during the course of the study.
- •Another invasive malignancy in the last 2 years (except basal cell carcinoma or squamous cell carcinoma of the skin, asymptomatic prostate cancer requiring only hormonal therapy and with normal prostate-specific antigen for > 1 year, and tumors deemed by the investigator to be of low likelihood for recurrence).
- •Prothrombin time/international normalized ratio (INR) and activated partial thromboplastin time or partial thromboplastin time (aPTT/PTT) > 1.3 × ULN or outside the therapeutic range of the local laboratory if receiving therapeutic anticoagulation that would affect the prothrombin time/INR, participants with a history of a hypercoagulation event within 6 months, or participants who have known hypercoagulation risk factors will be excluded.
- •The above information is not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
研究组 & 干预措施
SAR448501 dose escalation
Experimental
SAR448501 will be administered for up to 52 weeks. Different cohorts with up to 8 dose levels will be included.
干预措施: SAR448501 (Drug)
结局指标
主要结局
Incidence of treatment-emergent adverse event (TEAE)
时间窗: Baseline to 28 days post last dose
Potential pharmacologically optimized dose/regimen(s) of SAR448501 / DR-0201 in participants with R/R B-NHL
时间窗: Cycle 1 (Day 1 to Day 28)
Potential pharmacologically optimized dose/regimen(s) of SAR448501/DR-0201 in participants with R/R B-NHL as determined using an integrated assessment of efficacy, safety, pharmacokinetic (PK)/pharmacodynamic (PD), and exposure-response relationships
次要结局
- Response rate assessed for CLL(Baseline until disease progression (up to the end of treatment at Week 52))
- Response rate assessed for all other B-NHL lymphomas(Baseline until disease progression (up to the end of treatment at Week 52))
- Duration of response/remission (DOR)(Baseline until disease progression (up to the end of treatment at Week 52))
- Complete response/remission rate (CRR)(Baseline until the end of treatment (Week 52))
- Time to response (TTR in months)(Baseline until the end of treatment (Week 52))
- Progression-free survival (PFS)(Baseline until disease progression (up to the end of treatment at Week 52))
- Overall survival (OS)(Baseline until disease progression (up to the end of treatment at Week 52))
- Assessment of pharmacokinetic (PK) parameters: AUC0-t(Baseline to 28 days post last dose)
- Assessment of PK parameters: Cmax(Baseline to 28 days post last dose)
- Assessment of PK parameters: Tmax(Baseline to 28 days post last dose)
- Assessment of PK parameters: terminal elimination half-life(Baseline to 28 days post last dose)
- Incidence of anti-drug antibodies (ADAs)(Baseline to 28 days post last dose)
研究者
研究点 (16)
Loading locations...
相似试验
招募中
1 期
A Study of BL-M08D1 in Patients With Locally Advanced or Metastatic Solid TumorsNCT06718621Sichuan Baili Pharmaceutical Co., Ltd.22
招募中
1 期
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Lower Expression Gastrointestinal Cancer and Other Solid TumorsSolid TumorColorectal CancerPancreatic CancerGastric CancerEsophageal CancerNCT06500052Sichuan Baili Pharmaceutical Co., Ltd.20
招募中
1 期
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid TumorsSolid TumorBreast CancerNCT06503783Sichuan Baili Pharmaceutical Co., Ltd.20
尚未招募
1 期
A Study of KQ-2003 CAR-T Cell Therapy for Patients With Relapsed or Refractory POEMS SyndromePOEMS SyndromeNCT06518876Novatim Immune Therapeutics (Zhejiang) Co., Ltd.21
招募中
1 期
A Study to Assess Safety and Preliminary Efficacy of LP-108 Combined With Azacitidine In Subjects With AML, MDS, CMMLMyelodysplastic SyndromesChronic Myelomonocytic LeukemiaAcute Myeloid LeukemiaNCT05641259Guangzhou Lupeng Pharmaceutical Company LTD.198